Adoptive immunotherapy of cancer using chimeric antigen receptor (CAR)-engineered T cells with redirected specificity showed efficacy in recent trials. In preclinical models, ‘second-generation’ CARs ...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
Significant progress in understanding T cell signalling, particularly with respect to T cell co-receptors such as the co-stimulatory receptor CD28, has been made in recent years. This knowledge has ...
The total amount of money invested in the project. The total cost includes EU contribution as well as other project costs not covered by EU funding. It is expressed in euros. Amount of money, by way ...
JANX013 is a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific designed to further enhance the durability of anti-tumor immune responses in combination with Janux’s PSMA-targeted T ...
Use of PD-L1 and ICOSL to discriminate innate and adaptive dendritic cells in the head and neck cancer microenvironment.
This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
Janux Therapeutics, Inc. has dosed the first patient in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with ...
Scientists at Regeneron found that combining a novel class of CD28 bispecific antibodies with the anti-PD-1 therapy Libtayo led to improved anti-tumor activity in mice. (Sanofi and Regeneron) (Sanofi ...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results